# A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol

> **NCT07744386** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Male Volunteers

## Interventions

- **DRUG:** Dabigatran Etexilate
- **DRUG:** Rosuvastatin
- **DRUG:** CHF10196

## Key facts

- **NCT ID:** NCT07744386
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-27
- **Primary completion:** 2028-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744386, "A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*